Back to top
more

ICU Medical (ICUI)

(Delayed Data from NSDQ)

$96.90 USD

96.90
143,274

+1.02 (1.06%)

Updated Apr 18, 2024 04:00 PM ET

After-Market: $96.88 -0.02 (-0.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy18.00%
3Hold9.44%
4Sell5.10%
5Strong Sell2.53%
S&P50011.08%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (91 out of 251)

Industry: Medical - Products

Better trading starts here.

Zacks News

ICU Medical (ICUI) Q2 Earnings and Revenues Lag Estimates

ICU Medical (ICUI) delivered earnings and revenue surprises of -18.93% and 1.39%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

ICU Medical (ICUI) Surpasses Q1 Earnings Estimates

ICU Medical (ICUI) delivered earnings and revenue surprises of 1.68% and 0.67%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks.com featured highlights include Meridian Bioscience, OP Bancorp, ICU Medical and Pangaea Logistics Solutions

Meridian Bioscience, OP Bancorp, ICU Medical and Pangaea Logistics Solutions have been highlighted in this Screen of the Week article.

ICU Medical (ICUI) is a Great Momentum Stock: Should You Buy?

Does ICU Medical (ICUI) have what it takes to be a top stock pick for momentum investors? Let's find out.

Is Hepion Pharmaceuticals, Inc. (HEPA) Stock Outpacing Its Medical Peers This Year?

Here is how Hepion Pharmaceuticals, Inc. (HEPA) and ICU Medical (ICUI) have performed compared to their sector so far this year.

Nilanjan Banerjee headshot

Buy These 4 Low-Beta Stocks to Combat the Choppy Market

It is imperative to build a portfolio of low-beta stocks to sail through a choppy market. Meridian (VIVO), OP Bancorp (OPBK), ICU Medical (ICUI) and Pangaea Logistics (PANL) are well poised to gain.

Is ICU Medical (ICUI) a Solid Growth Stock? 3 Reasons to Think " Yes "

ICU Medical (ICUI) possesses solid growth attributes, which could help it handily outperform the market.

Is Aptinyx Inc. (APTX) Outperforming Other Medical Stocks This Year?

Here is how Aptinyx Inc. (APTX) and ICU Medical (ICUI) have performed compared to their sector so far this year.

Looking for a Growth Stock? 3 Reasons Why ICU Medical (ICUI) is a Solid Choice

ICU Medical (ICUI) is well positioned to outperform the market, as it exhibits above-average growth in financials.

ICU Medical (ICUI) Surpasses Q4 Earnings and Revenue Estimates

ICU Medical (ICUI) delivered earnings and revenue surprises of 11.66% and 6.30%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate ICU Medical (ICUI) to Report a Decline in Earnings: What to Look Out for

ICU Medical (ICUI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Cardiovascular Systems (CSII) Reports Q2 Loss, Misses Revenue Estimates

Cardiovascular Systems (CSII) delivered earnings and revenue surprises of -64.29% and 5.70%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

3 Reasons Why ICU Medical (ICUI) Is a Great Growth Stock

ICU Medical (ICUI) possesses solid growth attributes, which could help it handily outperform the market.

ICU Medical (ICUI) Q3 Earnings and Revenues Surpass Estimates

ICU Medical (ICUI) delivered earnings and revenue surprises of 15.64% and 6.96%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate ICU Medical (ICUI) to Report a Decline in Earnings: What to Look Out for

ICU Medical (ICUI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Company News for Sep 9, 2021

Companies In The News Are: COIN, TSLA, SPB, ICUI

ICU Medical (ICUI) Q2 Earnings and Revenues Beat Estimates

ICU Medical (ICUI) delivered earnings and revenue surprises of 14.63% and 5.02%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: ICU Medical (ICUI) Q2 Earnings Expected to Decline

ICU Medical (ICUI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ICU Medical (ICUI) Q1 Earnings and Revenues Top Estimates

ICU Medical (ICUI) delivered earnings and revenue surprises of 5.88% and 4.55%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate ICU Medical (ICUI) to Report a Decline in Earnings: What to Look Out for

ICU Medical (ICUI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ICU Medical (ICUI) Surpasses Q3 Earnings and Revenue Estimates

ICU Medical (ICUI) delivered earnings and revenue surprises of 48.44% and 13.53%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: ICU Medical (ICUI) Q3 Earnings Expected to Decline

ICU Medical (ICUI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ICU Medical (ICUI) Looks Good: Stock Adds 8.1% in Session

ICU Medical (ICUI) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.

Trina Mukherjee headshot

Medical Products Stock Earnings on Aug 10: CGC, SDGR & More

Despite the impact of the pandemic on the second quarter, Medical Product companies have shown strength on the back of huge adoption of COVID-19 related healthcare-support products and services.

Analysts Estimate ICU Medical (ICUI) to Report a Decline in Earnings: What to Look Out for

ICU Medical (ICUI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.